Recovery for Replimune: Accelerated Approval for Cancer Drug Twice Spurned by FDA
Frank Vinluan / medcitynews - Replimune went from an FDA rejection to a resubmission, a positive advisory committee vote, and finally an accelerated regulatory approval for advanced melanoma — all in less than four months. The FDA nod for Replimune’s oncolytic viral therapy, Tudriqev,…
AI Summary: After two previous turns in the penalty box, the FDA granted accelerated approval to Replimune’s oncolytic immunotherapy Tudriqev (RP1) in combination with nivolumab for advanced melanoma. The decision follows a favorable advisory committee outcome and positions a once-spurned viral-based therapy back into the clinic as a new option for patients with limited choices.
- Clinical community reaction and rollout: experts and training (4)
- Regulatory comeback: FDA approves Tudriqev after two rejections (4)
- Replimune announcements and company leadership reactions (3)
- All Other Stories
Clinical community reaction and rollout: experts and training
Regulatory comeback: FDA approves Tudriqev after two rejections
Replimune announcements and company leadership reactions
All Other Stories
FDA approves Moderna’s mRNA flu vaccine
Ella Jeffries / beckershospitalreview - The FDA has approved Moderna’s mFLUSIVA (mRNA-1010), the first mRNA-based influenza vaccine in the U.S., for the prevention of seasonal influenza in adults ages 50 and older. The decision follows a monthslong regulatory process that included the agency’s …
AI Summary: The FDA has approved Moderna's mRNA flu vaccine, giving the familiar seasonal bug a high-tech reboot. Regulators cleared Moderna’s mRNA formulation for public use, signaling a shift toward next-generation influenza vaccines; rollout details, target groups and supply plans will follow as public health authorities coordinate distribution for the coming flu season.
- FDA's reversal and approval of Moderna mRNA flu shot (3)
- Public health guidance and flu season preparedness (3)
- What mFLUSIVA approval means for policy, coverage and mRNA (3)
FDA's reversal and approval of Moderna mRNA flu shot
Public health guidance and flu season preparedness
What mFLUSIVA approval means for policy, coverage and mRNA
Swallowing faecal capsules reduces peanut allergy in six adults
Alice Klein / newscientist - Altering the gut microbiomes of people with peanut allergy using faeces donated from an allergy-free individual improved their peanut tolerance in a clinical trial
AI Summary: A small human trial showed swallowing fecal microbiota capsules reduced peanut allergy responses in six adults, while parallel animal and mechanistic work implicates bile-acid metabolites in restoring oral tolerance. The findings revive interest in microbiome-based desensitization, though larger trials are required before anyone starts prescribing ‘poop pills’ as routine therapy.
This amino acid may help the body fight tumors and viral infections
medicalxpress - The amino acid arginine helps keep the human body humming, most notably by synthesizing proteins that carry out a range of cellular processes. It's produced by our bodies and found in common high-protein foods. Low levels of arginine are associated with a…
AI Summary: New research implicates the amino acid histidine in modulating immune and tumor biology, suggesting it may enhance anti-tumor responses and antiviral defenses in preclinical studies. Scientists report mechanistic insights that could inform future therapeutic strategies, although translation to patients will require careful testing—because promising mouse data still need to pass the human audit.
FDA approves Simtriyo for treating ADHD in children and adults
medicalxpress - The U.S. Food and Drug Administration has approved Simtriyo (centanafadine) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and children 6 years and older weighing ≥20 kg.
AI Summary: The FDA granted approval for Simtriyo to treat attention‑deficit/hyperactivity disorder in children and adults, adding a new prescription option to the ADHD toolkit. Regulators highlighted efficacy and safety data supporting the decision; clinicians and patients will now weigh the drug’s profile against existing therapies as rollout and coverage decisions play out.
Prediction Market Betting on Drug Trials and Approvals Sparks Concern About Undermining Research
Rebecca Robbins / nytimes - Prediction markets on Kalshi and Polymarket now let people wager money on drug approvals. Kalshi also plans to allow bets on clinical trial results.
AI Summary: Betting platforms have started offering markets on clinical trial outcomes and FDA decisions, stirring alarms among regulators and researchers. Critics warn these markets could incentivize insider trading, leak-sensitive information, or distort trial conduct, prompting calls for oversight and clearer rules to protect scientific integrity and participant safety — because apparently Wall Street needed another hobby.
FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma
esmo - Evidence for efficacy is based on the results from the LITESPARK-022 study
AI Summary: Regulators have cleared the combination of belzutifan and pembrolizumab as adjuvant therapy for renal cell carcinoma at high risk of recurrence after nephrectomy. Clinical data showed improved disease‑free survival versus control, offering a new post‑surgery option intended to delay recurrence in patients with residual recurrence risk.
New treatment approach improves survival, reduces recurrence risk in muscle-invasive bladder cancer
medicalxpress - Researchers have found that a combination of enfortumab vedotin and pembrolizumab helps patients with muscle-invasive bladder cancer live longer while reducing the risk that their cancer will return after surgery, according to an international phase 3 cli…
AI Summary: Practice‑changing data and a network meta‑analysis have clarified perioperative strategies for muscle‑invasive bladder cancer, showing that certain neoadjuvant and adjuvant approaches improve survival and reduce recurrence. Recent trial results and comparative evidence are prompting shifts in treatment sequencing for cisplatin‑eligible patients, moving the needle on standards of care.
- Biomarkers and AI Predict Immunotherapy Benefit and Toxicity (4)
- EV‑Pembrolizumab: New Perioperative Standard for Cisplatin‑Eligible MIBC (4)
- Neoadjuvant Combinations and Bladder Preservation Trials (4)
- Network Meta-Analysis Clarifies Optimal Perioperative Strategies (3)
- All Other Stories
Biomarkers and AI Predict Immunotherapy Benefit and Toxicity
EV‑Pembrolizumab: New Perioperative Standard for Cisplatin‑Eligible MIBC
Neoadjuvant Combinations and Bladder Preservation Trials
Network Meta-Analysis Clarifies Optimal Perioperative Strategies
All Other Stories
It has begun: Foxconn amassing army of workers for iPhone 18 Pro assembly
appleinsider - Months ahead of the fall launches, and historically right on time, Apple supply chain partner Foxconn has started to hire a small army of assemblers to build the iPhone 18 Pro.Workers at a Foxconn facility - Image source: FoxconnEach summer, the Apple sup…
AI Summary: Agenus has suspended the BATTMAN clinical trial and announced a follow‑on program called ROBBIN after strategic reassessment, a move that has raised questions about transparency and participant communication. The abrupt pivot highlights tensions between rapid corporate decision‑making and the need to maintain patient trust in oncology research.
The AACR Rare Cancers Initiative: Uniting Researchers, Undoing Barriers, and Unleashing Progress
Steve Schneible / aacr - At the recent AACR Special Conference on Breaking Barriers in the Fight Against Rare Cancers, AACR Immediate Past President Lillian L. Siu, MD, FAACR, announced the AACR Rare Cancers Initiative. Learn more about how this new Initiative will marshal global…
AI Summary: The AACR has unveiled a Rare Cancers Initiative to coordinate researchers, streamline data sharing, and speed therapeutic development for uncommon tumor types. By pooling expertise, funding and networks, the program seeks to overcome the chronic scarcity of trials and resources that leave rare‑cancer patients waiting for attention that’s been hard to come by.
Live attenuated vaccines alone or in combination with an adenovirus-based vaccine protect mice lacking IFN-γ against pneumonic plague
Emily K. Hendrix, Jian Sha, Paul B. Kilgore, Blake H. Neil, Atul K. Verma, Heidi Spratt, Ashok K. Ch / science - Science Translational Medicine, Volume 18, Issue 859, July 2026.
AI Summary: Preclinical work shows that a live attenuated vaccine, alone or combined with an adenovirus vector, protected mice lacking key interferon‑gamma defenses from pneumonic plague. The strategy delivered surprising protection in immunocompromised models, suggesting a potential path forward for vaccines designed to work even when classical immune pathways are impaired.
Gregory Lesinski: Winship Team Publishes Novel CAR/VIPRa T-Cell Therapy in Science
oncodaily - Gregory Lesinski, Associate Director of Basic Research at Winship Cancer Institute of Emory University, shared on LinkedIn by Sarwish Rafiq, Assistant Professor at the Emory University School of Medicine and […]
AI Summary: Researchers published a novel CAR T‑cell approach exploiting the VIP–VIPR pathway that reprograms cells for superior antitumor activity in preclinical models. The Winship team’s paper reports enhanced tumor killing and durability in laboratory studies, flagging a promising route to improve CAR T efficacy in solid tumors — still very early, but intriguing.
Could this enzyme help remove 'zombie' cells from our tissues?
medicalxpress - Our population is aging. The United Nations reports that by 2050, the number of people age 85 and older on our planet is set to triple. But a longer life span isn't the same as a longer health span (the number of years we spend healthy). Salk Institute sc…
AI Summary: Researchers identified an enzyme that selectively targets senescent “zombie” cells, restoring tissue function in preclinical models and hinting at anti‑aging and therapeutic possibilities. The findings generated excitement for potential disease‑modifying strategies, but experts caution that translating enzyme‑based fixes from mice to humans will require careful safety studies and sober expectations.
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial
Adam D. Cohen / nature - Nature Medicine, Published online: 22 July 2026; doi:10.1038/s41591-026-04522-3In a phase 1 trial, the maximum tolerated dose for an FcRH5-containing bispecific T cell engager was not reached, and there was an encouraging response rate in patients with re…
AI Summary: A phase 1 study of the FcRH5×CD3 bispecific antibody cevostamab reported manageable safety and early signals of activity in relapsed or refractory multiple myeloma. Investigators outlined dosing, adverse events and preliminary responses, setting the stage for larger studies and combination trials as patients and advocates watch for broader access to T‑cell‑engaging therapies.
$10B M&A Deal Pays Off With GSK’s First Lung Cancer Drug Approval
Frank Vinluan / medcitynews - GSK drug Jideytro received FDA approval for treating advanced cases of non-small cell lung cancer driven by ROS1 alterations. This molecule came from Nuvalent, which GSK recently acquired for $10.6 billion. The post $10B M&A Deal Pays Off With GSK’s First…
AI Summary: GSK has won FDA approval for its first lung cancer drug, a gene-targeting therapy that validates the company’s heavy investment and recent M&A strategy. The approval follows pivotal trial evidence of clinical benefit and positions GSK competitively in thoracic oncology, offering a new therapeutic choice for patients with the relevant molecular profile.
Two Children With a Rare Epilepsy Mutation Show Improvement After Personalized Genetic Treatment
discovermagazine - Learn how personalized genetic therapy helped researchers treat two children with a rare form of epilepsy, enabling one to walk independently for the first time.
AI Summary: Two children with a rare, treatment‑resistant epilepsy mutation showed marked clinical improvement after receiving individualized genetic therapies—one via an antisense oligonucleotide tailored to the mutation. The cases underscore the promise of bespoke molecular medicines for devastating pediatric neurological disorders and hint that precision medicine can be both life‑changing and, yes, kind of miraculous.
How we are engineering bacteria to eat cancer
medicalxpress - Modern medicine has made significant advances in cancer treatments over the decades. But all cancer therapies still face one critical challenge: how to target cancers without damaging healthy cells.
AI Summary: Researchers engineered bacteria that selectively attack and consume tumor tissue in preclinical models, demonstrating promising tumor control and a novel mechanism to deliver anti‑cancer effects. Significant questions remain about safety, immune responses and delivery in humans, so while the “bacteria that eat cancer” headline is delightful, translation to patients will require cautious, rigorous steps.
Researchers identify immune cell that builds cancer-fighting hubs inside tumors
medicalxpress - Researchers at the Icahn School of Medicine at Mount Sinai have identified the immune cell that acts as the architect and coordinator of powerful immune hubs that form inside tumors and plays a key role in antitumor immunity. This discovery could lead to …
AI Summary: Researchers discovered a subset of dendritic cells that orchestrate formation and maintenance of tertiary lymphoid structures—local immune “hubs”—inside tumours. These niches concentrate and sustain anti-tumour T cells, explaining how some cancers spontaneously marshal immune responses and opening avenues to boost immunotherapy by enhancing or mimicking this dendritic cell-driven architecture.
- Discovery: dendritic cells build tumour immune hubs (3)
- Molecular and systemic regulators of tumour immune hubs (3)
- Therapeutic strategies: boosting T cells and DC vaccines (3)
Discovery: dendritic cells build tumour immune hubs
Molecular and systemic regulators of tumour immune hubs
Therapeutic strategies: boosting T cells and DC vaccines
Stephen Liu: AstraZeneca Reaches Deal with Dizal to Bring Sunvozertinib to the US!
oncodaily - Stephen Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared on X: “FINALLY! AstraZeneca reaches deal with Dizal […]
AI Summary: AstraZeneca reached a deal to make sunvozertinib available in the U.S., accelerating global access for patients with EGFR exon 20 insertion–positive non–small cell lung cancer. The move follows encouraging WU-KONG1B data and signals commercial partnerships are finally translating niche trial gains into real-world treatment options for a stubbornly underserved subgroup.
- AstraZeneca-Dizal deal opens US access to sunvozertinib (3)
- Testing, treatment gaps and rising rare-NSCLC approvals (3)
- WU-KONG1B confirms sunvozertinib activity in EGFR Exon20 (3)
AstraZeneca-Dizal deal opens US access to sunvozertinib
Testing, treatment gaps and rising rare-NSCLC approvals
WU-KONG1B confirms sunvozertinib activity in EGFR Exon20
The RAS Inhibitor Daraxonrasib is Showing Encouraging New Results – Dana-Farber
oncodaily - Dana-Farber Cancer Institute shared a post on LinkedIn: “For years, RAS was considered one of the toughest targets in cancer research. In pancreatic cancer, that challenge is especially urgent. New […]
AI Summary: A targeted RAS inhibitor, daraxonrasib, produced promising clinical activity in patients with NRAS-mutant melanoma, demonstrating tumor responses and a tolerable safety profile in early studies. The data suggest a viable therapeutic avenue for a historically hard-to-treat subset and justify larger trials to confirm benefit — because apparently NRAS wasn’t going to cure itself.